Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, osteopontin (OPN), non-small-cell lung cancer (NSCLC), immunohistochemistry (IHC), disease-free survival, overall survival, ENDOTHELIAL GROWTH-FACTOR, PROGRESSION, INFLAMMATION, METASTASIS, MARKER, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Osteopontin, Prognosis, Sialoglycoproteins, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Osteopontin (OPN) is a multifunctional protein, which has recently been shown to be linked to tumorigenesis, progression and metastasis in different malignancies. Since non-small-cell lung cancer (NSCLC)'s prognosis remains bad, with few predictors of outcome, the purpose of this study was to evaluate if OPN might be involved in NSCLC's biology and therefore represent a prognostic marker and a target for new therapeutic trials. Immunohistochemistry was used to detect OPN expression, evaluated as percentage of neoplastic cells with cytoplasmic immunoreactivity, in a wide cohort of patients with stage I NSCLC (136 cases). The median value of this series (20% of positive cells) was used as the cutoff value to distinguish tumours with low (<20%) from tumours with high (> or =20%) OPN expression. A statistically significant correlation between high levels of OPN and shorter overall (P = 0.034) and disease-free (P = 0.011) survival in our patients was shown. Our results support the hypothesis that high OPN expression is a significantly unfavourable prognostic factor for the survival of patients with stage I NSCLC. This conclusion has notable importance in terms of the biological characterization of early-stage tumours and therapeutic opportunities.